Skip to Content
Merck
  • Effects of phonophoresis of piroxicam and ultrasound on symptomatic knee osteoarthritis.

Effects of phonophoresis of piroxicam and ultrasound on symptomatic knee osteoarthritis.

Archives of physical medicine and rehabilitation (2012-10-16)
Wanwadee Luksurapan, Jariya Boonhong
ABSTRACT

To compare the effects of phonophoresis of piroxicam (PhP) and ultrasound therapy (UT) in patients with mild to moderate, symptomatic knee osteoarthritis (OA). A randomized, double-blind, controlled trial. Department of rehabilitation medicine, university hospital. Patients with knee OA (N=46; mean age ± SD, 58.91±10.50y) who had visual analog scale (VAS) scores of 50 to 92mm (mean, 71.5mm) for knee pain intensity and Kellgren-Lawrence grades of I to III were randomly allocated into 2 groups: PhP and UT (23 in each group). Both the PhP and UT groups were treated with an ultrasound program using the stroking technique, continuous mode, 1.0W/cm(2), 10 minutes per session, and 5 times per week for 2 weeks. Four grams of 0.5% piroxicam gel (20mg of piroxicam drug) was used in the PhP group, while the nondrug coupling gel was used in the UT group. A 100-mm VAS for usual pain and the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) were evaluated before and after treatment in both groups using a double-blinded procedure. The VAS and total WOMAC scores were significantly improved after treatment in both groups (P<.001). The PhP group showed more significant effects than the UT group, both in reducing the VAS pain score (P=.009) and in improving the WOMAC score, although it did not reach the level of significance (P=.143). Our results indicated that PhP was significantly more effective than UT in reducing pain and tended to improve knee functioning in Kellgren-Lawrence grades I to III knee OA. PhP is suggested as a new, effective method for treatment of symptomatic knee OA.

MATERIALS
Product Number
Brand
Product Description

Piroxicam, European Pharmacopoeia (EP) Reference Standard
Piroxicam for system suitability, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Piroxicam, meets USP testing specifications
Sigma-Aldrich
Piroxicam, ≥98% (TLC)